Loading...
Loading...
KRTX| Name | Value |
|---|---|
| Revenues | 5.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 5.3M |
| Operating Expense | 70.3M |
| Operating I/L | -65.1M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.5M |
| Pretax | -64.4M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -64.9M |
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in creating and delivering innovative medicines for individuals with psychiatric and neurological conditions. The company's primary product candidate, KarXT, is an oral modulator of muscarinic receptors currently in Phase III clinical trials for the treatment of acute psychosis in schizophrenia patients. Additionally, KarXT is being developed for addressing negative and cognitive symptoms of schizophrenia, psychosis, and dementia-related psychosis. Karuna Therapeutics also focuses on developing other muscarinic-targeted drug candidates and has strategic partnerships with Eli Lilly and Company, Zai Lab (Shanghai) Co., Ltd, PureTech Health LLC, Charles River Laboratories, and PsychoGenics, Inc.
